Ongoing Trials in Endometrial Cancer

Opinion
Video

An overview of ongoing research in the endometrial cancer treatment space.

Transcript:

Ritu Salani, MD, MBA: The other complexity is that several other abstracts presented at this meeting looked at I/O [immuno-oncology] combinations, mostly checkpoint inhibitors. There was adalimumab-axitinib, which was presented in the mismatch repair [MMR]–proficient population, in recurrent or persistent endometrial cancer. There’s apatinib-camrelizumab. There’s cediranib-olaparib, olaparib-durvalumab, or cediranib-durvalumab in women with recurrent persistent ovarian cancer. We’re seeing similar concepts with different agents being explored. I’d love to hear your take on those studies. They’re informative, but they’re challenged because of this new shifting landscape. I’ll open it up to the panel if you want to take any trial that was presented.

Shannon N. Westin, MD, MPH, FACOG: Several of those trials are ongoing. GY012 was doing olaparib in various combinations and durvalumab in various combinations. That’s in the second line in patients who haven’t had I/O, a PARP inhibitor, or anything else. If there’s intriguing activity, those types of things might get moved into earlier lines of therapy. To that point, we’re already awaiting the results of DUO-E, a randomized phase 3 trial that has 3 arms. Similar to GY018 and RUBY, it has an arm of a PD-L1 inhibitor compared with placebo, but the third arm takes durvalumab and adds olaparib to it. The results are in, but we don’t have them yet. The press release notes that the primary end points are positive for both arms, both the durvalumab-alone arm as well as the durvalumab-olaparib arm. That will be presented soon and will determine if that’s going to impact our care of patients who are not only the mismatch repair deficient but also proficient, depending on the impact of that regimen.

Ursula A. Matulonis, MD: That will be interesting to see. But that’s the perfect study to set the standard of care around whether we’re going to use PARP inhibitors in this setting and the best patient population.... Endometrial cancers have underlying HRD [homologous recombination deficiency]. I’ll comment on the 2 other trials that were that were presented. One was presented in the plenary session on the combination of I/O and VEGF inhibition. From our group, Betsy Lee presented avelumab and axitinib in a poster. Both trials, much like lenvatinib-pembrolizumab, have very significant response rates. About 40% are really benefiting. These trials confirm the activity of pembrolizumab-lenvatinib.

Ritu Salani, MD, MBA: Can you talk a little about RUBY Part 2?

Matthew A. Powell, MD: RUBY Part 2 adds in those additional arms to add in a PARP inhibitor and niraparib with dostarlimab as a maintenance strategy for patients after carboplatin-paclitaxel. Like in RUBY, they get dostarlimab with carboplatin-paclitaxel, and you add in the niraparib after. That has completed accrual, and we should have data in the next year. We hope the MMR-proficient population, as we would guess, is going to benefit from the addition of a PARP inhibitor. It’s yet to be seen. This is 1 more area in which we try to understand how best to personalize medicine for our patients.

Transcript edited for clarity.

Related Videos
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Ramez N. Eskander, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Elias Jabbour, MD
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Related Content
Chao Cao, PhD, MPH

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

April 25th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, Moores Cancer Center, the University of California, San Diego Health

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet — Copenhagen University Hospital

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Debu Tripathy, MD, professor, chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer

April 22nd 2024
Article